Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
Terminated · Phase 2, Phase 3 · NCT05555615
Conditions: Irritability Associated With Autism Spectrum Disorder
At a glance
- Research payments reported, 2025
- $470,947
- U.S. investigators named
- 19
- Sites paid
- 20
- Planned or actual enrollment
- 209
About the trial
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Tested
- Pimavanserin (drug)
- Dates
- Started 2022-11-02; completion 2025-02-14
- Results posted
- Yes
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).
From ClinicalTrials.gov, last updated 2025-12-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Acadia Pharmaceuticals Inc reported $470,947 in research payments for this study in 2025 (72 payments).
Products named: Acp-103
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Raun Melmed, MD Developmental-Behavioral Pediatrics · Scottsdale, AZ
- Elysa J. Marco, M.D. Neurology · San Francisco, CA
- Kevin A. Shapiro, MD, PHD Child Neurology · Pasadena, CA
- Isaac Melamed, M.D. Specialist · Centennial, CO
- Adelaide Robb, MD Neurology · Washington, DC
- Morteza Nadjafi, M.D. Psychiatry · Orlando, FL
- Elias H. Sarkis, MD Child & Adolescent Psychiatry · Gainesville, FL
- Riaz A. Baber, M.D. Psychiatry · Naperville, IL
- Mcleod Gwynette, MD Child & Adolescent Psychiatry · Shreveport, LA
- Ann Childress Child & Adolescent Psychiatry · Las Vegas, NV
- Mark Dibuono, MD Psychiatry · Staten Island, NY
- Diab Almhana, MD Psychiatry · Avon Lake, OH
- Ernest Pedapati, M.D. Child & Adolescent Psychiatry · Cincinnati, OH
- Amanda Bennett, MD Developmental-Behavioral Pediatrics · Philadelphia, PA
- Lawrence D. Ginsberg, M.D. Psychiatry · Houston, TX
- Sejal S. Mehta, M.D. Psychiatry · Plano, TX
- Bradley J. Musser, M.D. Family Medicine · Richardson, TX
- James A. Knutson, M.D. Prescribing Psychologist · Kirkland, WA
- Steven A. Phillips, MD Pediatrics · Tacoma, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cortica Inc $101,736
- Relaro Medical Trials $72,202
- Anzoni $57,632
- Childrens Research Institute $53,289
- Core Clinical Research $32,702
- Apg Research $21,813
- Southwest Autism Research Center $21,368
- Immunoe Research Centers $14,840
- Musc Medical Center, SC $13,999
- Cincinnati Children's Hospital Medical Center, OH $11,700
- Aim Trials $11,533
- Apg Research LLC $9,039
- Children's Hospital of Philadelphia, PA $8,531
- Amr Baber Research Group $7,727
- Richmond Behaivoral Associates $7,599
- Southwest Autism Research $7,232
- Quest Therapeutics of Avon Lake $6,975
- Clinical Research of Southern Nevada $6,058
- Tacoma General Allenmore Hospital, WA $4,150
- Red Oak Psychiatry Associates $821
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.